Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Harrow Inc
(NQ:
HROW
)
10.19
-0.43 (-4.05%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harrow Inc
< Previous
1
2
3
4
Next >
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
April 25, 2024
From
Harrow, Inc.
Via
Business Wire
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
April 02, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
March 19, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/30
May 30, 2023
Via
Investor Brand Network
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
March 05, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
February 15, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Announces New Appointments to its Board of Directors
January 29, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/9
May 09, 2023
Via
Investor Brand Network
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
January 11, 2024
From
Harrow, Inc.
Via
Business Wire
Melt Pharmaceuticals Provides Corporate Update
January 03, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 03, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 29, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow to Present at Two Investor Conferences in November
November 20, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Announces Third Quarter 2023 Financial Results
November 13, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
October 30, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
October 24, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
September 29, 2023
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
September 26, 2023
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Announces Second Quarter 2023 Financial Results
August 09, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Launches VIGAMOX® in the U.S.
July 31, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
July 26, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Prices $60 Million Public Offering of Common Stock
July 19, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
July 18, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
July 18, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Announces Proposed Public Offering of Common Stock
July 18, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
July 18, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
May 17, 2023
From
Harrow
Via
Business Wire
NASDAQ:HROW Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties at Harrow Health, Inc
May 16, 2023
San Diego, CA -- (SBWIRE) -- 05/16/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Harrow Health, Inc.
Via
SBWire
Harrow Announces First Quarter 2023 Financial Results
May 11, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 04, 2023
From
Harrow
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.